ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sanofi and Sinovac Biotech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

SanofiSinovac Biotech
studies on the registry2,425163
open to participants now10536
phase 3 studies under way6117
reach primary completion within a year6615
programswith a study of their own in two years81+12 named only32

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSanofiSinovac Biotech
Phase 128%13%
Phase 2

Sanofi: 25 of its 81 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. BLU-808phase 2

and 20 more — sign in to see them all

31%
28%
Phase 3

Sanofi: 22 of its 81 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

27%
34%
Approved, new studies

Sanofi: 11 of its 81 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Sinovac Biotech: 8 of its 32 programs at approved, new studies

  1. experimental vaccineapproved, new study
  2. Chickenpox Vaccineapproved, new study
  3. EV71approved, new study
  4. Poliovirus Vaccine, Inactivatedapproved, new study
  5. 1wIPV+2sIPVapproved, new study

and 3 more — sign in to see them all

25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sanofi30 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702
  5. BLU-808phase 2 · Dec 31 · NCT06931405

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
Sinovac Biotech9 readouts · 7 phase 3

Sinovac Biotech, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. experimental vaccineapproved, new study · Nov 0 · NCT07505888

Sinovac Biotech, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)phase 1 · Dec 0 · NCT07889193
  2. Rabies Vaccine (Serum-free Vero Cell), Freeze-driedphase 3 · Dec 30 · NCT07055295

Sinovac Biotech, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. EV71approved, new study · Jan 9 · NCT07793175
  2. Rabies vaccinephase 3 · Jan 30 · NCT07055893

Sinovac Biotech, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Anflu®approved, new study · Feb 0 · NCT07832201

Sinovac Biotech, Mar ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Sinovac PCV13phase 3 · Mar 0 · NCT07832500
  2. SNA02-48phase 3 · Mar 31 · NCT07633119
·····

Sinovac Biotech, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)phase 3 · Sep 15 · NCT07793227
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Sinovac Biotech

New programs 3

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionSanofiSinovac Biotech
Influenza, Humanboth · compare here
Pneumococcal Infectionsboth · compare here
Chickenpoxboth · compare here

Sinovac Biotech in Chickenpox: 3 programs

  1. PROVARIXphase 3
  2. Chickenpox Vaccineapproved, new study
  3. Vaicella Vaccine+DTaP on Day 0, MMR on Day 30approved, new study

Their studies: Sinovac Biotech’s studies of Chickenpox in search

COVID-19both · compare here

Sanofi in COVID-19: 3 programs

  1. NVX-COV2705phase 3
  2. Biological Productsphase 1
  3. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study

Their studies: Sanofi’s studies of COVID-19 in search

Sinovac Biotech in COVID-19: 1 program

  1. Rabies vaccinephase 3

Their studies: Sinovac Biotech’s studies of COVID-19 in search

Meningitis, Meningococcalboth · compare here

Sanofi in Meningitis, Meningococcal: 1 program

  1. MenACYW conjugate vaccineapproved, new study

Their studies: Sanofi’s studies of Meningitis, Meningococcal in search

Sinovac Biotech in Meningitis, Meningococcal: 3 programs

  1. Rabies vaccinephase 3
  2. high-dose Group ACYW135X Meningococcal Conjugate Vaccinephase 1
  3. experimental vaccineapproved, new study

Their studies: Sinovac Biotech’s studies of Meningitis, Meningococcal in search

Meningococcal Infectionsboth · compare here

Sinovac Biotech in Meningococcal Infections: 1 program

  1. Chickenpox Vaccineapproved, new study

Their studies: Sinovac Biotech’s studies of Meningococcal Infections in search

Streptococcal Infectionsboth · compare here

Sanofi in Streptococcal Infections: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Streptococcal Infections in search

Sinovac Biotech in Streptococcal Infections: 2 programs

  1. Chickenpox Vaccineapproved, new study
  2. Poliovirus Vaccine, Inactivatedapproved, new study

Their studies: Sinovac Biotech’s studies of Streptococcal Infections in search

Malariaboth · compare here

Sanofi in Malaria: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Malaria in search

Sinovac Biotech in Malaria: 1 program

  1. Rabies vaccinephase 3

Their studies: Sinovac Biotech’s studies of Malaria in search

Measlesboth · compare here

Sanofi in Measles: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Measles in search

Sinovac Biotech in Measles: 1 program

  1. Chickenpox Vaccineapproved, new study

Their studies: Sinovac Biotech’s studies of Measles in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Sanofi 54 of 81 · Sinovac Biotech 21 of 32 programs (10 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).